Type: drug
Status: Active — Modified Release Formulation
Developer: Pfizer
After initial twice-daily dosing showed tolerability issues, Pfizer reformulated danuglipron as a once-daily modified-release tablet. Phase 2b data (2025) with the new formulation showed HbA1c reduction of -1.2% and body weight loss of -6.9% at 32 weeks with improved GI tolerability. Phase 3 trials launched mid-2025.
Small molecule non-peptide GLP-1 receptor agonist. Modified-release formulation provides extended plasma exposure, reducing peak-to-trough fluctuations that drove GI side effects with immediate-release dosing.
Year: 2025-2026